Core Insights - The A-share market has seen a significant rally in innovative drug concept stocks, with notable increases in share prices for several companies [1] Group 1: Stock Performance - Guangxi Shengtang (广生堂) experienced a rise of approximately 18% [2] - Shutaishen (舒泰神) increased by over 12% [2] - Jimin Health (济民健康) and Anglikang (昂利康) both hit the 10% daily limit up [2] - Huahai Pharmaceutical (华海药业) rose by over 9% [2] - Frontier Biologics (前沿生物) increased by over 8% [2] - Hanyu Pharmaceutical (翰宇药业) saw a rise of over 7% [2] - Saily Medical (塞力医疗) and Jiuzhou Pharmaceutical (九洲药业) both increased by over 6% [2] Group 2: Market Capitalization and Year-to-Date Performance - Guangxi Shengtang has a market capitalization of 19.2 billion with a year-to-date increase of 269.02% [2] - Shutaishen has a market capitalization of 17.3 billion with a year-to-date increase of 389.07% [2] - Jimin Health has a market capitalization of 5.76 billion with a year-to-date increase of 61.56% [2] - Anglikang has a market capitalization of 8.31 billion with a year-to-date increase of 213.50% [2] - Huahai Pharmaceutical has a market capitalization of 31.4 billion with a year-to-date increase of 18.92% [2] - Frontier Biologics has a market capitalization of 5.544 billion with a year-to-date increase of 51.64% [2] - Hanyu Pharmaceutical has a market capitalization of 19.2 billion with a year-to-date increase of 68.35% [2] - Saily Medical has a market capitalization of 5.628 billion with a year-to-date increase of 270.91% [2] - Jiuzhou Pharmaceutical has a market capitalization of 18.5 billion with a year-to-date increase of 56.50% [2]

Core Viewpoint - The innovative drug concept stocks experienced a significant surge in early trading on October 15, with several companies reaching their daily price limits and notable increases in stock prices [1]. Group 1: Stock Performance - Angli康 reached the daily limit up, indicating strong investor interest [1]. - Guangshengtang saw a rise of over 10%, with a notable increase of 14.41% in its stock price [2]. - Other companies such as Saili Medical, Shutaishen, Rongchang Bio, and Lianhuan Pharmaceutical also experienced substantial gains, contributing to the overall positive trend in the innovative drug sector [1]. Group 2: Notable Stock Increases - Guangshengtang (300436) reported a stock increase of 116.94%, with a rise of 14.41% [2]. - Pinlikang (002940) increased by 41.20%, with a rise of 10.01% [2]. - Saili Medical (603716) saw a 27.12% increase, with an 8.35% rise [2]. - Shutaishen (300204) experienced a 34.77% increase, with a 7.88% rise [2]. - Jimin Health (603222) rose by 10.64%, with a 6.72% increase [2]. - Lianhuan Pharmaceutical (600513) increased by 20.21%, with a 6.37% rise [2]. - Rongchang Bio (688331) saw a 97.06% increase, with a 6.31% rise [2]. - Zhendong Pharmaceutical (300158) increased by 6.95%, with a 5.95% rise [2]. - Kangchen Pharmaceutical (035500) rose by 48.68%, with a 4.91% increase [2]. - Maiwei Niwu-U (688062) saw a 46.58% increase, with a 4.86% rise [2].

Core Points - The resignation of independent director Hu Yiqiao due to personal reasons will not reduce the number of independent directors below the legal requirement, but it will affect the composition of the board's specialized committees [1][2] - The company held a half-year performance briefing on October 13, 2025, to discuss financial status and development strategies with investors [3][4] Summary by Sections Resignation of Independent Director - Hu Yiqiao has submitted her resignation as an independent director and from various committee roles due to personal reasons [1] - The resignation will take effect after the company adjusts its specialized committees, although she will continue to fulfill her duties until then [1][2] Half-Year Performance Briefing - The performance briefing was conducted online, featuring key executives including the chairman and general manager [3] - The company disclosed its R&D expenses for the first half of the last three years: 33.52 million in 2023, 67.58 million in 2024, and 68.42 million in 2025 [5] - The company is focusing on innovation-driven development, with significant R&D investments, including 277 million for 2024, representing 12.82% of revenue, and 145 million for the first half of 2025, accounting for 11.26% of revenue [5] - The company is actively pursuing new drug development in various therapeutic areas and has multiple products at different clinical trial stages [5]

Core Points - Hu Yiqiao, an independent director of Lianhuan Pharmaceutical, has resigned from her position due to personal reasons [2] - Following her resignation, Hu Yiqiao will no longer hold any position within the company [2]

证券代码：600513 证券简称：联环药业 公告编号：2025-078 江苏联环药业股份有限公司 关于 2025 年半年度业绩说明会召开情况的公告 答:尊敬的投资者，您好！公司 2023 年上半年研发费用 3,352.30 万元、2024 年上半年研发费用 6,757.95 万元、2025 年上半年研发费用 6,842.39 万元,详情 请见公司相关定期报告，谢谢您的关注！ 2、您好！请问贵公司的 LH-1801 的代谢途径是仍经肝脏吗？是否有与达格 列净相比毒副作用更低的预期。 答：尊敬的投资者,您好！感谢您对公司的关注！公司 LH-1801 经过肝脏代 谢，正同步开展在不同程度肝功能不全和肾功能不全受试者中 PK/PD 和安全性研 究。在Ⅲ期临床试验中，与二甲双胍联合项目中的阳性药物为达格列净片，旨在 进行头对头的对比研究。请您持续关注公司发布的相关公告，谢谢。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 江苏联环药业股份有限公司（以下简称"公司"）于 2025 年 10 月 13 日 10:00-11:00, 通 过 ...

证券代码：600513 证券简称：联环药业 公告编号：2025-079 2025 年 10 月 14 日 1 胡一桥女士的辞职不会导致公司独立董事人数少于董事会人数的三分之一， 但将会导致董事会专门委员会中独立董事所占比例不符合法律法规及专门委员 会工作细则的规定，根据《中华人民共和国公司法》《上市公司独立董事管理办 法》《公司章程》等有关规定，在公司董事会调整各专门委员会前，胡一桥女士 将继续按照相关法律法规履行独立董事和董事会专门委员会相关职务职责，其辞 职将在公司调整完成各专门委员会后生效。 截至本公告披露日，胡一桥女士未持有公司股份，不存在应履行未履行的事 项。胡一桥女士在担任公司独立董事期间，恪尽职守、勤勉尽职，为促进公司稳 健发展、规范治理等方面发挥了积极的作用，公司及董事会对胡一桥女士担任公 司独立董事期间为公司发展作出的贡献表示衷心的感谢！ 特此公告。 江苏联环药业股份有限公司董事会 江苏联环药业股份有限公司 关于独立董事辞职的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 江苏联环药业股份有限公司（以下 ...

757 ZHONG LUN 152 中倫律師事務所 特殊的普通合伙 Limited Liability Partnership 北京中伦(成都)律师事务所 关于 江苏联环药业股份有限公司 深圳·广州·武汉·成都·重庆·青岛·杭州·南京·海口·东京·香港·伦敦·纽约·洛杉矶·旧金山·阿拉木图 · Oingdao · Hangzhou · Naniing · Haikou · Tokyo · Hong Kong · London · New York · Los Ang 2025 年第三次临时股东会 的 法律意见书 二〇二五年九月 法律意见书 北京中伦(成都)律师事务所 关于江苏联环药业股份有限公司 2025 年第三次临时股东会的 法律意见书 致:江苏联环药业股份有限公司 根据《中华人民共和国公司法》(下称"《公司法》")、《上市公司股东 会规则》（以下简称"《股东会规则》"）、《律师事务所从事证券法律业务管 理办法》(以下简称"《证券法律业务管理办法》")、《律师事务所证券法律 业务执业规则(试行)》(以下简称"《证券法律业务执业规则》")等相关法 律、行政法规、规章、规范性文件以及《江苏联环药业股份有限公司章 ...

证券代码：600513 证券简称：联环药业 公告编号：2025-077 江苏联环药业股份有限公司 2025年第三次临时股东会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 一、会议召开和出席情况 (一)股东会召开的时间：2025 年 9 月 30 日 (二)股东会召开的地点：扬州生物健康产业园健康一路 9 号联环药业会议室 (三)出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： | 1、出席会议的股东和代理人人数 | 547 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 6,080,636 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股份总数的比例（%） | 3.5440 | (四)表决方式是否符合《公司法》及《公司章程》的规定，股东会主持情况 等。 本次会议经过适当的召集和通知程序，由公司董事长钱振华先生主持，采用 了现场投票与网络投票相结合的表决方式，符合《中华人民共和国公司法》、中 国证监会《上市公 ...

Core Viewpoint - Jiangsu Lianhuan Pharmaceutical Co., Ltd. is holding a half-year performance briefing on October 13, 2025, to discuss its operational results and financial status for the first half of 2025, allowing investors to engage in Q&A sessions [2][3][4]. Group 1: Meeting Details - The performance briefing is scheduled for October 13, 2025, from 10:00 to 11:00 AM [2][4]. - The meeting will take place at the Shanghai Stock Exchange Roadshow Center, accessible online [2][4]. - Investors can submit questions from September 26, 2025, to October 10, 2025, before 4:00 PM through the Roadshow Center website or via the company's email [2][5]. Group 2: Participants - Key participants include Chairman Qian Zhenhua, General Manager Niu Ben, Chief Financial Officer Xue Hao, Independent Director Zhang Bin, and Securities Affairs Representative Ge Kai [4]. Group 3: Investor Participation - Investors can participate online during the meeting and will receive timely responses to their questions [5]. - After the meeting, the main content and outcomes will be available for viewing on the Roadshow Center website [5].

证券代码：600513 证券简称：联环药业 公告编号：2025-076 江苏联环药业股份有限公司 江苏联环药业股份有限公司（全文简称"公司"）已于 2025 年 8 月 27 日发 布《公司 2025 年半年度报告》，为便于广大投资者更全面深入地了解公司 2025 年半年度经营成果、财务状况，公司计划于 2025 年 10 月 13 日（星期一） 10:00-11:00 举行 2025 年半年度业绩说明会，就投资者关心的问题进行交流。 一、说明会类型 关于召开 2025 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 会议召开时间：2025 年 10 月 13 日（星期一）10:00-11:00 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2025 年 09 月 26 日（星期五）至 10 月 10 日（星期五）16:00 前 ...